ISIN:DE000A0B65S3

EQS-News: PAION AG implements resolved capital reduction

Retrieved on: 
Samstag, April 15, 2023

Aachen (Germany), 31 March 2023 – PAION AG (ISIN DE000A0B65S3; Frankfurt Stock Exchange, Prime Standard: PA8), a specialty pharmaceutical company with innovative compounds for use in outpatient and in-hospital sedation, anesthesia and intensive care announces that the resolutions of the Extraordinary General Meeting of PAION AG on 25 January 2023 regarding the reductions of the share capital have been entered into the commercial register at the local court of Aachen on 14 March 2023.

Key Points: 
  • Aachen (Germany), 31 March 2023 – PAION AG (ISIN DE000A0B65S3; Frankfurt Stock Exchange, Prime Standard: PA8), a specialty pharmaceutical company with innovative compounds for use in outpatient and in-hospital sedation, anesthesia and intensive care announces that the resolutions of the Extraordinary General Meeting of PAION AG on 25 January 2023 regarding the reductions of the share capital have been entered into the commercial register at the local court of Aachen on 14 March 2023.
  • The share capital of the Company, which amounted to EUR 71,336,992.00 at the Extraordinary General Meeting, was reduced to EUR 7,133,699.00 by registration of the resolutions of the Extraordinary General Meeting.
  • In case of a fractional settlement required for this purpose, the shareholders of PAION AG will be contacted by their custodian banks for the execution.
  • Expected from 12 April 2023, the converted shares will be traded under ISIN DE000A3E5EG5 and the stock exchange symbol PA8K.

EQS-News: PAION AG reports on fiscal year 2022

Retrieved on: 
Freitag, März 31, 2023

PAION has further advanced the commercialization of angiotensin II in 2022.

Key Points: 
  • PAION has further advanced the commercialization of angiotensin II in 2022.
  • In China, PAION entered into a patent assignment agreement for remimazolam (trade name Ruima®) with Humanwell in early 2022.
  • In April 2022, PAION and Cristália signed an exclusive license agreement for the development and commercialization of remimazolam in Latin America.
  • PAION also continued to expand its sales structures in the second half of 2022.

EQS-News: PAION IS HOSTING A SPONSORED ANGIOTENSIN II SYMPOSIUM AT ISICEM IN BRUSSELS

Retrieved on: 
Donnerstag, März 16, 2023

One abstract about angiotensin II has been accepted for a presentation.

Key Points: 
  • One abstract about angiotensin II has been accepted for a presentation.
  • In addition, PAION has organised a Sponsored Symposium.
  • Poster number P219
    This post hoc analysis helps to understand which group of patients might be further studied to determine benefits from treatment with angiotensin II.
  • Angiotensin II mimics the body’s endogenous angiotensin II peptide, which is central to the renin-angiotensin-aldosterone system, which in turn regulates blood pressure.

EQS-News: PAION AG: Extraordinary General Meeting approves capital reductions and creates scope for further corporate financing

Retrieved on: 
Donnerstag, Februar 2, 2023

At the meeting, shareholders approved the proposed capital reductions by redemption and consolidation of shares with a large majority.

Key Points: 
  • At the meeting, shareholders approved the proposed capital reductions by redemption and consolidation of shares with a large majority.
  • In order to achieve an even reduction ratio, the share capital will be reduced to EUR 71,336,990.00 in a first step.
  • The entry of the capital reductions in the commercial register is expected to take place in March 2023, subject to any actions of annulment.
  • For further corporate financing, we will carefully consider the options available to us.”

EQS-News: ​​​​​​​PAION ANNOUNCES SUBMISSION OF NEW DRUG APPLICATION FOR REMIMAZOLAM BY ITS LICENSEE CRISTÁLIA IN BRASIL

Retrieved on: 
Donnerstag, Februar 2, 2023

Thus, the Latin American remimazolam licensee Cristália Produtos Quimicos Farmaceuticos Ltda, Brazil (“Cristália”) informed PAION about the submission of a New Drug Application (NDA) to the Brazilian Health Regulatory Agency (ANVISA) for remimazolam in both indications general anesthesia and procedural sedation.

Key Points: 
  • Thus, the Latin American remimazolam licensee Cristália Produtos Quimicos Farmaceuticos Ltda, Brazil (“Cristália”) informed PAION about the submission of a New Drug Application (NDA) to the Brazilian Health Regulatory Agency (ANVISA) for remimazolam in both indications general anesthesia and procedural sedation.
  • The NDA submission triggers a milestone payment of EUR 1 million from Cristália.
  • Gregor Siebert, CEO of PAION AG, commented: “We congratulate our partner Cristália on the submission of a marketing authorization application for remimazolam in Brazil.
  • We are very proud of this first submission in the biggest pharma market in Latin America, which once again demonstrates the global potential of remimazolam.